To increase the public’s access to naloxone, pharmacies can dispense naloxone kits (both intra-nasal and injectable formats) free-of-charge to eligible individuals without the need for a prescription through the Ontario Naloxone Program for Pharmacies (ONPP). Claims for reimbursement of these naloxone kits can be submitted through the Health Network System (HNS) subject to compliance with the Ministry’s policy. For more information, please refer to the following:
- Updated Executive Officer Notice: Ontario Naloxone Program for Pharmacies (May 5, 2025) (Note: this is subject to updates; please refer to the latest version for the most up to date information.)
- Updated Questions and Answers Document: Ontario Naloxone Program for Pharmacies (May 5, 2025) (Note: this is subject to updates; please refer to the latest version for the most up to date information.)
- Naloxone Kit Supplies List
Pharmacy professionals are responsible for ensuring they possess sufficient knowledge, skills, and abilities to competently provide naloxone in a safe and effective manner. OPA offers a Take-home Naloxone Program in Community Pharmacies module as part of the free Addictions and Opioid Agonist Therapy Education program, which was developed to provide education on naloxone in the treatment of opioid overdose and to assist pharmacists with educating patients and/or patient representatives on naloxone. Members are also encouraged to refer to the Ontario College of Pharmacists’ webpage on Naloxone – Dispensing, Selling or Providing for more information.
Disclaimer: The Ontario Pharmacists Association (OPA) provides this material to pharmacy professionals for informational purposes only. It is intended to provide pharmacy professionals with general guidance on dispensing naloxone. The information provided may not be comprehensive and does not replace professional judgement and responsibilities. It is provided without warranty of any kind by OPA and OPA assumes no responsibility for any errors, omissions or inaccuracies therein. The decision for use and application of this document is the responsibility of the user. OPA assumes no liability for such use and application or any resulting outcomes. It is the responsibility of the pharmacy professional to use professional judgment in evaluating this material in light of any relevant clinical or situational data. It is intended to supplement materials provided by regulatory authorities, and should there be any discrepancies, municipal, provincial, and federal laws, policies and guidelines shall prevail. This information provided is current as of the date of publication. Pharmacy professionals are encouraged to confirm information with additional resources.
